Progyny, Inc.

NASDAQ:PGNY

Medical - Healthcare Information Services

Healthcare
$36.16 -0.19%

-$0.05 today

Market cap
$2.66B
Beta
1.04
P/E (TTM)
31.4
EPS (TTM)
$0.84
52W Low $16.10High $28.75

Volume 0.88M

Average 1.49M

PGNY Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Progyny, Inc.NASDAQ: PGNY

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables turns positive

Q2 FY2026 accounts payables was $27.84M, compared with -$4.41M a year earlier. Trailing-twelve-month accounts payables was $45.02M. Over 3 fiscal years it compounded at -15.5% a year.

Context

  • Accounts payables amounted to 2.2% of revenue in FY2025, down 0.4 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly accounts payables holds near $27.84M or moves back toward the trailing-twelve-month quarterly average of $11.26M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$27.84M-17.2% QoQ
Last fiscal yearDec 2025
$28.75M+195.0% YoY
LTMJun 2026
$45.02M+493.0% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+731.2%——
1 year+195.0%——
3-year CAGR-15.5%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
28.75M USD
Year-over-year change
+195.0%
4-year CAGR
+12.7%

Accounts Payables vs competitors

How PGNY compares with its peers on the latest reported figures

  • PGNY's LTM Jun 2026 accounts payables of $45.02M is the largest of the 3 companies compared; the peer median is $2.11M.
  • Its year-over-year change of +493.0% is the highest of 3, against a peer median of +232.7%.
  • Accounts payables amounts to 3.4% of revenue for PGNY, versus a peer median of 1.0%.
PGNY Competitors Peer median
Accounts Payables for PGNY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PGNYProgyny, Inc.LTM Jun 2026$45.02M +493.0%-15.5%3.4%
HQYHealthEquity, Inc.LTM Jul 2026$8.1M +274.4%—0.6%
OMDAOmada HealthLTM Mar 2026$3.88M +191.0%—1.4%
Peer median (excluding PGNY) $2.11M+232.7%—1.0%

Competitors are the stored peer set for PGNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income65.77M30.36M62.04M54.34M58.52M
Depreciation & Amortization1.3M1.6M2.28M3.18M4.95M
Deferred Income Tax(33.3M)(6.62M)3.75M(10.46M)(8.12M)
Stock-Based Compensation33.71M100.75M122.61M128.13M131.87M
Change in Working Capital(51.26M)(59.49M)(17.42M)(11.78M)2.8M
Accounts Receivables(68.68M)(119.3M)(21.74M)(9.87M)(5.12M)
Inventory00000
Accounts Payables17.84M47.69M16.24M(30.27M)28.75M
Other Working Capital(421K)12.12M(11.92M)28.37M(20.84M)
Other Non-Cash Items9.82M13.79M15.56M15.7M20.17M
Operating Cash Flow26.04M80.4M188.81M179.11M210.19M
Capital Expenditures(2.13M)(3.24M)(3.64M)(5.41M)(18.41M)
Acquisitions (Net)000(5.3M)(9.34M)
Purchases of Investments(111.48M)(163.33M)(429.69M)(170.34M)(354.96M)
Sales of Investments122.37M122.71M232.81M376.84M223.7M
Other Investing Activities00000
Investing Cash Flow8.77M(43.87M)(200.53M)195.79M(159.01M)
Debt Repayment00000
Common Stock Issued4.27M4.23M6.13M2.4M1.23M
Common Stock Repurchased000(300.28M)(81.66M)
Dividends Paid00000
Other Financing Activities(17.97M)(12.09M)(17.2M)(12M)(18.94M)
Financing Cash Flow(13.7M)(7.86M)(11.07M)(309.88M)(99.36M)
Effect of Forex Changes001K1K62K
Net Change in Cash21.11M28.67M(22.78M)65.02M(48.12M)
Free Cash Flow23.91M77.15M185.17M173.7M191.78M

Progyny, Inc.

NASDAQ:PGNY

Intrinsic Alpha fair value

Locked

Current Price

$36.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.